Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

FDA grants accelerated approval to asciminib for adult patients with newly diagnosed Ph+ CML in chronic phase

On October 29, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to asciminib for adult patients with…

Read More

FDA approves marstacimab for patients with hemophilia A or B without inhibitors

On October 11, 2024, the U.S. Food and Drug Administration (FDA) granted the approval of marstacimab for patients aged 12…

Read More

Insights into the treatment and management of BPDCN: CD123-targeted agents & combination therapy

VJHemOnc is pleased to share a feature article which explores the challenges associated with treating BPDCN.  This article covers promising…

Read More

FDA approves axatilimab for the treatment of chronic graft-versus-host disease

On August 14, 2024, the U.S. Food and Drug Administration (FDA) approved axatilimab as a treatment for chronic graft-versus-host disease…

Read More

Trial in Focus: NUTRIVENTION – dietary evidence in cancer care

VJHemOnc is excited to share a feature on the rationale, design, and aims of the NUTRIVENTION trial (NCT04920084).

Read More

EHA 2024 press briefing rundown

VJHemOnc is thrilled to bring you the latest updates from the 29th Congress of the European Hematology Association (EHA) held…

Read More

FDA grants accelerated approval to epcoritamab for relapsed/refractory follicular lymphoma

On June 26, 2024, the U.S. Food and Drug Administration (FDA) approved epcoritamab for the treatment of adult patients with…

Read More

FDA approves first-in-class telomerase inhibitor imetelstat for transfusion-dependent LR-MDS

On June 6, 2024, the U.S. Food and Drug Administration (FDA) approved imetelstat for adults with low- to intermediate-1 risk…

Read More

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals